FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On March 19, 2018, Fibrocell Science, Inc. issued a press release announcing financial results for the year ended December 31, 2017 and recent operational highlights. A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
Item 8.01 Other Events.
On March 19, 2018, Fibrocell Science, Inc. posted an updated Corporate Presentation on its website www.fibrocell.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Fibrocell Science, Inc. ExhibitEX-99.1 2 a031618finalfcscfy2017ea.htm EXHIBIT 99.1 a031618finalfcscfy2017ea
Fibrocell Reports 2017 Financial Results and Recent Highlights
- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT –
EXTON,…To view the full exhibit click here
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.